Page 7 - Flipbook

Adjuvant BEP x 1 for Stage I NSGCT

• 246 CSI NSGCT with lymphovascular invasion (CSIB)

• Single-arm study: all received BEP x 1

• Primary end-point: “malignant recurrence at 2 years”

• Secondary end-point: “benign recurrence”

• E.g. Teratoma

• Median follow-up: 49 months

Results: Malignant Recurrence @ 2yrs: 1.3%

Conclusions: Adoption of BEPx1 as standard

would reduce overall exposure to chemo